Literature DB >> 8560412

Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients.

T Abumiya1, T Yamaguchi, T Terasaki, T Kokawa, K Kario, H Kato.   

Abstract

Although tissue factor pathway inhibitor (TFPI) plays an essential role in the regulation of blood coagulation, the quantitative changes in its levels in thrombotic disease are still undefined. We compared TFPI activity in ischemic stroke patients and control subjects matched for age and cholesterol level to determine whether TFPI activity is changed in the disease. TFPI activity was significantly lower in the stroke patients (1.01 +/- 0.24 U/ml) than in the control subjects (1.10 +/- 0.16 U/ml). In relation to clinical subtypes of stroke, TFPI activity in atherothrombotic infarction (0.93 +/- 0.19 U/ml) and lacunar infarction (0.99 +/- 0.23 U/ml) was significantly lower than in the control subjects, whereas the level in cardioembolic infarction (1.16 +/- 0.31 U/ml) was not. No relationship could be established between TFPI activity and other haemostatic parameters reflecting the production of thrombin/fibrin and the activation of fibrinolysis. These results may suggest that the moderately lower TFPI activity in stroke patients could be due to atherosclerotic changes rather than to consumptive coagulopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8560412

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.

Authors:  David A Hinds; Alfonso Buil; Daniel Ziemek; Angel Martinez-Perez; Rainer Malik; Lasse Folkersen; Marine Germain; Anders Mälarstig; Andrew Brown; Jose Manuel Soria; Martin Dichgans; Nan Bing; Anders Franco-Cereceda; Juan Carlos Souto; Emmanouil T Dermitzakis; Anders Hamsten; Bradford B Worrall; Joyce Y Tung; Maria Sabater-Lleal
Journal:  Hum Mol Genet       Date:  2016-02-09       Impact factor: 6.150

2.  Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.

Authors:  Jacques E Rossouw; Karen C Johnson; Mary Pettinger; Mary Cushman; Per Morten Sandset; Lewis Kuller; Frits Rosendaal; Jan Rosing; Sylvia Wasserthal-Smoller; Lisa W Martin; Joann E Manson; Kamakshi Lakshminarayan; Jose G Merino; John Lynch
Journal:  Stroke       Date:  2012-02-23       Impact factor: 7.914

3.  Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor.

Authors:  Giovanni Cimmino; Plinio Cirillo; Massimo Ragni; Stefano Conte; Giuseppe Uccello; Paolo Golino
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

4.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

5.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; İrfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

6.  Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.

Authors:  Cihangir Erem; Irfan Nuhoglu; Mustafa Kocak; Mustafa Yilmaz; Safiye Tuba Sipahi; Ozge Ucuncu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

Review 7.  Hemostasis and alterations of the central nervous system.

Authors:  Gregory J del Zoppo; Yoshikane Izawa; Brian T Hawkins
Journal:  Semin Thromb Hemost       Date:  2013-10-28       Impact factor: 4.180

8.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

9.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.

Authors:  Bülent Alioğlu; Nevin Kılıç; Enver Şimşek; Yıldız Dallar
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.